Lacosamide
Links shared publicly online about this topic
Study confirms efficacy and tolerability of lacosamide for uncontrolled POS
news-medical.net — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.” View full resource at news-medical.net
Most Recently Shared on February 26, 2010 at 5:41 am By:
Study confirms efficacy and tolerability of lacosamide for uncontrolled POS: A recent multi-center study has confi... http://bit.ly/9sdJGi
ingentaconnect Carbamazepine/lacosamide interaction: Epileptic negative myoclonu...
ingentaconnect.com — “ingentaconnect Carbamazepine/lacosamide interaction: Epileptic negative myoclonu...” View full resource at ingentaconnect.com
Most Recently Shared on May 19, 2011 at 9:21 am By:
Carbamazepine/lacosamide interaction: Epileptic negative myoclonus: case report: (Source: Reactions) http://bit.ly/imyEcq
Lacosamide Validated As Promising Therapy For Uncontrolled Partial-Onset Seizures
medicalnewstoday.com — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seiz” View full resource at medicalnewstoday.com
Most Recently Shared on February 26, 2010 at 4:07 pm By:
Lacosamide Validated As Promising Therapy For Uncontrolled Partial-Onset Seizures http://mnt.to/3ybp #epilepsy
Internal Med Medical News about Diabetic Neuropathies Pain Lacosamide
mdlinx.com — “Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy” View full resource at mdlinx.com
Most Recently Shared on January 19, 2010 at 10:17 am By:
Int Med: Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy: Diabetes Care http://url4.eu/1ABhm
Neurology Medical News about Anticonvulsants Vigabatrin Lacosamide Rufinamide
mdlinx.com — “New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin” View full resource at mdlinx.com
Most Recently Shared on June 2, 2010 at 11:07 am By:
New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin: Current Treatment Options in Ne... http://bit.ly/an0oPO #neurology #mdlinx
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
physorg.com — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients. Researchers from the ...” View full resource at physorg.com
Most Recently Shared on February 25, 2010 at 7:11 pm By:
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures http://tw.physorg.com/186329360
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
sciencedaily.com — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures, and doses of 600mg/day may provide additional benefit for some patients.” View full resource at sciencedaily.com
Most Recently Shared on March 9, 2010 at 9:07 pm By:
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures A recent multi-center study has con.. http://bit.ly/8X1cZx
Study Reinforces Role Of AED Vimpat (Lacosamide) (C-V) As Add-On Treatment For POS
medicalnewstoday.com — “UCB has announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according” View full resource at medicalnewstoday.com
Most Recently Shared on March 12, 2010 at 4:11 pm By:
Study Reinforces Role Of AED Vimpat (Lacosamide) (C-V) As Add-On Treatment For POS http://mnt.to/3yQt #epilepsy
Sustained Efficacy Of Vimpat (Lacosamide) In Reducing Partial Onset Of Seizures For Up To Eight Years
medicalnewstoday.com — “The 29th International Epilepsy Congress in Rome, Italy (28th August-1st September) 1-4 presented consistent evidence this week, that a combined treatment with Vimpat® (lacosamide) has general” View full resource at medicalnewstoday.com
Most Recently Shared on September 2, 2011 at 7:04 am By:
Sustained Efficacy Of Vimpat (Lacosamide) In Reducing Partial Onset Of Seizures For Up To Eight Years: The 29th ... http://t.co/Mec2KWC
ScienceDirect - Epilepsy & Behavior : Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine
sciencedirect.com — “ScienceDirect - Epilepsy & Behavior : Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine” View full resource at sciencedirect.com
Most Recently Shared on May 22, 2011 at 3:53 am By:
Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine http://dx.doi.org/10.1016/j.yebeh.2011.01.022
Vimpat® (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless Of The Mechanism Of Action Of Concomitant Antiepileptic Drugs
medicalnewstoday.com — “Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 3:05 pm By:
Vimpat® (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless Of The Mechanism Of Action Of Concomi... http://mnt.to/3PXs
New Data For Vimpat (Lacosamide) C-V Showed Sustained Efficacy For Up To 5 Years
medicalnewstoday.com — “New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset s” View full resource at medicalnewstoday.com
Most Recently Shared on June 30, 2010 at 5:08 pm By:
New Data For Vimpat (Lacosamide) C-V Showed Sustained Efficacy For Up To 5 Years http://mnt.to/3Fzh #epilepsy
Research Supporting The Role Of Antiepileptic Drug Vimpat® (Lacosamide) (C-V) To Be Highlighted At Upcoming AAN Meeting
medicalnewstoday.com — “The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses at the 62nd annual American Academy of Neurology (AAN) meeting, taking place at the” View full resource at medicalnewstoday.com
Most Recently Shared on April 10, 2010 at 11:37 am By:
Research Supporting The Role Of Antiepileptic Drug Vimpat® (Lacosamide) (C-V) To Be Highlighted At Upcoming AAN Meeting .. http://dld.bz/P5D
New Oral Solution Formulation Of Antiepileptic Drug Vimpat (Lacosamide) (C-V)
medicalnewstoday.com — “UCB has announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilep” View full resource at medicalnewstoday.com
Most Recently Shared on June 16, 2010 at 12:14 pm By:
New Oral Solution Formulation Of Antiepileptic Drug Vimpat (Lacosamide) (C-V) http://mnt.to/3DVb #caregivers
Research Supporting Role Of AED Vimpat (Lacosamide)(C-V) Highlighted At AAN Meeting
medicalnewstoday.com — “The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses - both UCB-sponsored and independent - at the 62nd annual American Academy of Neuro” View full resource at medicalnewstoday.com
Most Recently Shared on April 12, 2010 at 2:07 pm By:
Research Supporting Role Of AED Vimpat (Lacosamide)(C-V) Highlighted At AAN Meeting http://mnt.to/3B6m #neurology
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Medical News from Around the World
-
Epilepsy OW
Organizing epilepsy resources shared by health experts, advocates, and organizations into WisdomCards.
-
MNT Epilepsy News
The latest epilepsy news published daily. Articles from research centers, universities and prestigious journals.
Advertisement

